Clinical Research
corporate_fare

Corflow Therapeutics AG

Address
Neuhofstrasse 3d

Sponsor Overview

assignment
1
sponsored trial
science
1
molecule
location_city
17
research centres
public
3
countries
person_search
17
investigators

Specializations

Acute Coronary Syndrome and Myocardial Infarction

Corflow Therapeutics AG focuses on ST-elevated myocardial infarction and related acute coronary syndrome presentations, with attention to patients experiencing microvascular obstruction after coronary reperfusion.

  • STEMI
  • STEACS
  • Microvascular obstruction

The sponsor's clinical interest centers on cardiovascular injury linked to impaired microcirculation and the treatment of coronary complications following acute ischemic events.

Intracoronary Therapeutic Delivery

Its research activity includes intracoronary infusion approaches designed to deliver therapeutic agents directly into the coronary circulation, with emphasis on localized treatment of damaged myocardial tissue.

  • Coronary infusion
  • Targeted cardiac delivery
  • Endovascular intervention

The therapeutic focus extends to delivery platforms intended to support treatment of coronary microvascular injury in the setting of acute infarction.

Microvascular Injury and Cardiac Tissue Protection

The sponsor is involved in research addressing microvascular injury, myocardial perfusion impairment, and markers associated with recovery of injured cardiac tissue after reperfusion.

  • Microvascular perfusion
  • Reperfusion injury
  • Myocardial salvage

These interests align with clinical efforts to assess injury patterns and treatment response in patients with coronary flow disturbance.

Biomarkers of Treatment Response

Corflow Therapeutics AG also explores markers of efficacy relevant to coronary intervention and myocardial recovery, including indicators of response to locally delivered therapeutic agents.

  • Efficacy biomarkers
  • Treatment response markers
  • Cardiovascular imaging endpoints

These areas support evaluation of therapeutic impact in acute coronary settings where microvascular damage is a central concern.

Sponsored Trials

Trial Name Country Status
Evaluation of Intracoronary Tirofiban and Adenosine via CoFI System for the Treatment of Microvascular Obstruction in Patients with ST-Elevation Myocardial InfarctionFrance FranceSpain SpainThe Netherlands The NetherlandsRecruiting

Data & Insights

science
Molecule Portfolio
Compounds under investigation
0
Exclusive Molecules
out of 1 total (0% not shared with other sponsors)

This sponsor works with 1 molecule, of which 0 are not being studied by other sponsors.

hub
Site Partnerships
Collaboration with research centres
0%
Return partnership rate
0 of 17 sites collaborated multiple times

This sponsor has worked with 17 sites across their trial portfolio.

Therapeutic Focus

  • 1.
    Cardiovascular Diseases1 trial
    359 other sponsors

Partnered Research Centres

17 centres
location_city
assignment192
Amphia Hospital
Address
Molengracht 21, 4818 CK Breda
Learn morearrow_forward
location_city
assignment680
Amsterdam UMC
Address
De Boelelaan 1117, 1081 HV Amsterdam
Learn morearrow_forward
location_city
assignment2
Centre Cardiologique D Evecquemont
Address
2 Rue Des Carrieres, 78740 Evecquemont
Learn morearrow_forward
location_city
assignment381
Centre Hospitalier Universitaire De Caen Normandie
Address
Avenue De La Cote De Nacre, 14000 Caen
Learn morearrow_forward
location_city
assignment1015
Centre Hospitalier Universitaire De Lille
Address
Rue Michel Polonovski, 59037 Lille
Learn morearrow_forward
location_city
assignment531
Centre Hospitalier Universitaire De Rennes
Address
16 Boulevard De Bulgarie, Bp 90349, 35200 Rennes
Learn morearrow_forward
Page 1 of 3

Want to get in touch with this sponsor?

Send a question and we'll pass it on to Corflow Therapeutics AG.

Need a custom report on this sponsor?

Competitive positioning, market entry, partnership opportunities — tell us the question.

Is something out of date?

Tell us what needs correcting and we'll update this profile.